Summary
34 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: $619.0M against $478.0M.
- The price moves less than the market (beta 0.56).
What to watch
- The company made a loss over the last 12 months.
- Operating profit does not even cover the interest on its debt.
- The share price is above the Bulios Fair Price.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 9.7% a year over 5 years. Over the last 3 years it grew by 4.7% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $16.0M.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 1.7 years of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
High, at risk- Yield
- 4.72%
- Raised in a row
- 3 years
You receive $2.40 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Neutral- Buy 3
- Hold 4
- Sell 1
Today's price within the analysts' price targets
The average target of $56.33 is 9.6% above today's price. 38% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
The company reports no revenue by product.
By region
- Northeast 28%
- West 21%
- Southwest 19%
- Central 18%
- Southeast 14%
Northeast brings in 28% of revenue. Southeast grew fastest, by 11% a year.
Segments in detail